T he pharmaceutical company Cortexyme announced that the first group of participants has been dosed in the Phase 1 clinical trial of its lead compound, COR388, for the treatment of Alzheimer’s disease.
Because no new successful developments have emerged in Alzheimer’s therapeutics in the last 15 years, researchers have been trying to discover new and innovative ways to treat the disease.